PharmiWeb.com - Global Pharma News & Resources
27-Aug-2018

Novartis receives European Commission approval of its CAR-T cell therapy, Kymriah® (tisagenlecleucel)

Media release (PDF)


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novartis International AG via GlobeNewswire
HUG#2212701

Editor Details

Last Updated: 28-Aug-2018